# An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201)

> **NCT04987242** · PHASE2 · COMPLETED · sponsor: **Allena Pharmaceuticals** · enrollment: 16 (actual)

## Conditions studied

- Hyperuricemia
- Gout
- Chronic Kidney Diseases

## Interventions

- **DRUG:** ALLN-346
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04987242
- **Lead sponsor:** Allena Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-16
- **Primary completion:** 2022-03-02
- **Final completion:** 2022-03-02
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04987242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04987242, "An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04987242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*